Processa Pharmaceuticals names four executives to leadership roles

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced four leadership appointments, according to a company statement released Nov. 4, 2026.

Gregory J. Flesher was named Chief Operating Officer. Flesher has more than 25 years of biopharmaceutical experience and previously served as chief executive officer of Ambros Therapeutics, Reneo Pharmaceuticals and Novus Therapeutics. He also held senior roles at Avanir Pharmaceuticals, InterMune, Amgen and Eli Lilly.

Craig Coburn, Ph.D., was appointed Executive Vice President and Head of Research. Coburn has more than 30 years of medicinal chemistry and drug discovery experience. He most recently served as Senior Vice President and Head of Chemistry for Pioneering Medicines at Flagship Pioneering and spent the first 20 years of his career at Merck Research Laboratories. Coburn also served as a scientific advisor to Vidya Therapeutics since 2024 and was among the scientists who helped invent VT-7208, the company's lead drug candidate.

Ashley Hall, J.D., was named Executive Vice President of Development. Hall most recently served as Chief Development Officer of Structure Therapeutics and previously held the same role at Reneo Pharmaceuticals. She also held senior positions at Esperion Therapeutics, Amgen, Micromet and MedImmune.

Michael P. Cruse was appointed Executive Vice President of Business Operations. Cruse has more than 20 years of operational experience and most recently served as Chief Operating Officer of Ambros Therapeutics, and previously as Chief Operating Officer of Reneo Pharmaceuticals.

The appointments follow Processa's July 2026 acquisition of Vidya Therapeutics through a reverse merger and a concurrent private placement financing of approximately $200 million. The company is advancing VT-7208, an oral Bruton's tyrosine kinase inhibitor, in planned Phase 2 studies covering food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis. The FDA has cleared an investigational new drug application for the planned Phase 2 study of VT-7208 in chronic spontaneous urticaria.

You May Also Be Interested In

• Medicus Pharma unit SkinJect signs non-binding SPAC merger LOI
• Worksport signs term sheet to acquire truck bed accessory business
• IonQ acquires Elisity in $1.15B all-stock deal for quantum security